Therapeutic Advances in Malignant Glioma: Current Status and Future Prospects

被引：22
作者：
Robins, H. Ian [1 ,2 ,3 ]
Lassman, Andrew B. [4 ,5 ]
Khuntia, Deepak [1 ]
机构：
[1] Univ Wisconsin, Dept Human Oncol, Sch Med & Publ Hlth, Madison, WI 53792 USA
[2] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Madison, WI 53792 USA
[3] Univ Wisconsin, Dept Neurol, Sch Med & Publ Hlth, Madison, WI 53792 USA
[4] Mem Sloan Kettering Canc Ctr, Dept Neurol, New York, NY 10065 USA
[5] Mem Sloan Kettering Canc Ctr, Brain Tumor Ctr, New York, NY 10065 USA
来源：
NEUROIMAGING CLINICS OF NORTH AMERICA | 2009年 / 19卷 / 04期
关键词：
Radiation sensitizers; Temozolomide; Glioblastoma; Pseudoresponse; Pseudoprogression; Targeted agents; PHASE-II TRIAL; GROWTH-FACTOR RECEPTOR; BEVACIZUMAB PLUS IRINOTECAN; MGMT PROMOTER METHYLATION; BRAIN-TUMOR CONSORTIUM; TYROSINE KINASE INHIBITOR; GLIOBLASTOMA-MULTIFORME; RECURRENT GLIOBLASTOMA; ADJUVANT CHEMOTHERAPY; TEMOZOLOMIDE;
D O I：
10.1016/j.nic.2009.08.015
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
This article reviews the current status and trends in the treatment of primary gliomas, focusing predominantly on glioblastoma. It also discusses the current standard of care and new targeted agents currently under investigation. Furthermore, the concepts of pseudoprogression and pseudoresponse are introduced, which are new imaging correlates that have significant impact on understanding of the disease.
引用
收藏
页码：647 / +
页数：11
相关论文
共 87 条
  • [1] Afra D, 2002, LANCET, V359, P1011
  • [2] AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients
    Batchelor, Tracy T.
    Sorensen, A. Gregory
    di Tomaso, Emmanuelle
    Zhang, Wei-Ting
    Duda, Dan G.
    Cohen, Kenneth S.
    Kozak, Kevin R.
    Cahill, Daniel P.
    Chen, Poe-Jou
    Zhu, Mingwang
    Ancukiewicz, Marek
    Mrugala, Maciej M.
    Plotkin, Scott
    Drappatz, Jan
    Louis, David N.
    Ivy, Percy
    Scadden, David T.
    Benner, Thomas
    Loeffler, Jay S.
    Wen, Patrick Y.
    Jain, Rakesh K.
    [J]. CANCER CELL, 2007, 11 (01) : 83 - 95
  • [3] Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse
    Brada, M
    Hoang-Xuan, K
    Rampling, R
    Dietrich, PY
    Dirix, LY
    Macdonald, D
    Heimans, JJ
    Zonnenberg, BA
    Bravo-Marques, JM
    Henriksson, R
    Stupp, R
    Yue, N
    Bruner, J
    Dugan, M
    Rao, S
    Zaknoen, S
    [J]. ANNALS OF ONCOLOGY, 2001, 12 (02) : 259 - 266
  • [4] How effective is BCNU in recurrent glioblastoma in the modern era?: A phase II trial
    Brandes, AA
    Tosoni, A
    Amistà, P
    Nicolardi, L
    Grosso, D
    Berti, F
    Ermani, M
    [J]. NEUROLOGY, 2004, 63 (07) : 1281 - 1284
  • [5] MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients
    Brandes, Alba A.
    Franceschi, Enrico
    Tosoni, Alicia
    Blatt, Valeria
    Pession, Annalisa
    Tallini, Giovanni
    Bertorelle, Roberta
    Bartolini, Stefania
    Calbucci, Fabio
    Andreoli, Alvaro
    Frezza, Giampiero
    Leonardi, Marco
    Spagnolli, Federica
    Ermani, Mario
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (13) : 2192 - 2197
  • [6] Epidermal growth factor receptor inhibitors in neuro-oncology: Hopes and disappointments
    Brandes, Alba A.
    Franceschi, Enrico
    Tosoni, Alicia
    Hegi, Monika E.
    Stupp, Roger
    [J]. CLINICAL CANCER RESEARCH, 2008, 14 (04) : 957 - 960
  • [7] Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas
    Brandsma, Dieto
    Stalpers, Lukas
    Taal, Walter
    Sminia, Peter
    van den Bent, Martinj
    [J]. LANCET ONCOLOGY, 2008, 9 (05) : 453 - 461
  • [8] Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas
    Burris, HA
    Hurwitz, HI
    Dees, EC
    Dowlati, A
    Blackwell, KL
    O'Neil, B
    Marcom, PK
    Ellis, MJ
    Overmoyer, B
    Jones, SF
    Harris, JL
    Smith, DA
    Koch, KM
    Stead, A
    Mangum, S
    Spector, NL
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (23) : 5305 - 5313
  • [9] Perfusion, diffusion and spectroscopy values in newly diagnosed cerebral gliomas
    Catalaa, Isabelle
    Henry, Roland
    Dillon, William P.
    Graves, Edward E.
    McKnight, Tracy R.
    Lu, Ying
    Vigneron, Daniel B.
    Nelson, Sarah J.
    [J]. NMR IN BIOMEDICINE, 2006, 19 (04) : 463 - 475
  • [10] Chakravarti A, 2002, CANCER RES, V62, P4307
123456789